$24.4B of 2025 neuroscience blockbuster sales lose US exclusivity by 2037, led by Ocrevus, Kesimpta, Vyvgart. These 17 public biotechs have 26 neuroscience treatments in Phase 3 or filed with the FDA, 8 of them already filed.
2025 sales each company reports from tracked neuroscience treatments losing US exclusivity by 2037. Big pharma has spent $59.8B on 7 neuroscience acquisitions since 2023. See the deals →
Ketamine manufacturing validation strengthens launch readiness ahead of November 10 ANDA goal
FDA decisions on relutrigine (Dec 27) and ulixacaltamide (Jan 29) approach after clean mid-cycle reviews; vormatrigine restarts after POWER1 missed
Azetukalner is filed in focal epilepsy as Xenon pauses new psychiatry enrollment
Durable SPS benefit supports miv-cel's filing path; FDA approval remains decisive
Larimar plans to complete its rolling BLA for nomlabofusp in 2H 2026, seeking accelerated approval on skin frataxin, with a mid-2027 launch target
AMT-130 BLA filed on three-year data; four-year analysis missed significance on cUHDRS
Biohaven licensed opakalim to SK Biopharmaceuticals and BHV-1300 in Asia to Ono, funding its Graves' disease Phase 3 after the troriluzole rejection
Ionis's own launches are growing; partner Roche reported Phase 3 sefaxersen data
AC Immune expects initial data by year-end on whether its NLRP3 inhibitor ACI-19764 lowers inflammation in patients, and plans FDA meetings on a Phase 2 expansion for its Parkinson's vaccine ACI-7104 in early 2027; cash of CHF 75.4 million lasts into Q4 2027
Coya prioritizes ALS; FTD start moves to 2027, runway guidance unchanged
HLP003 pivotal readout remains expected in Q4 2026 as leadership transition continues
Harrow still needs a sharp commercial ramp to deliver annual guidance
FDA accepted Intellia's BLA for lonvo-z in hereditary angioedema with Priority Review and a March 10, 2027 decision date; both nex-z Phase 3 trials resumed enrollment after FDA lifted its clinical holds
Ryoncil grows; back-pain results and LVAD filing remain key
Neuphoria is merging into Scancell, whose iSCIB1+ showed 77% 22-month PFS with ipilimumab and nivolumab in melanoma
OKYO's Phase 3 NEPTUNE trial of urcosimod in neuropathic corneal pain enrolled its first patients in October
Brepocitinib is approved and won two uveitis Phase 3s; FcRn data come in 2027
Filed treatments are listed first. This shows where late-stage treatments are being developed, not which companies will be acquired.
Pipeline data and summaries from Readouts as of 13 November 2026; companies already acquired are left out.
Oncology · Immunology · Cardiometabolic · Infectious disease · Other areas